POLARx Post Approval Study (POLARx PAS)

NCT06170606 | Active Not Recruiting FDA Device

• 1 other identifier: PY008
• Study Type: interventional
• Target: 200
• Locations: 1 country
• Sites: 6

Brief Summary

To collect clinical data on safety, effectiveness and procedural success of Boston Scientific's Cardiac Cryoablation System (includes all BSC commercially available POLARx/POLARx Fit catheters) when used to perform pulmonary vein isolation (PVI) in the ablation treatment of de novo Atrial Fibrillation (AF).

Conditions

Paroxysmal Atrial Fibrillation

Keywords

Cryoablation

Outcome Measures

Primary Outcomes (2)

• Percentage of Participants With Freedom From Primary Safety Events at 12 Months Post-procedure (Acute and Chronic Events) Using the Boston Scientific Cardiac Cryoablation System With POLARx Cryoablation Balloon Catheter Models

  This measure reports the observed safety event-free rate at 12 Months follow up for all treatment and intent subjects. The safety events are a composite of procedure-related and device-related adverse events. Acute Primary Safety Endpoints include: * Death * Myocardial infarction (MI) * Persistent gastroparesis/injury to vagus nerve * Transient ischemic attack (TIA) * Stroke/Cerebrovascular accident (CVA) * Thromboembolism/ Air embolism * Cardiac tamponade/perforation * Pneumothorax * Serious vascular access complications * Pulmonary edema/heart failure * AV block not attributable to medication effect or vasovagal reaction Chronic Primary Safety events (through 12 Months) include: * Atrial esophageal fistula * Pulmonary vein stenosis (≥ 70% reduction of diameter) OR presented by patient's symptoms at 12-Month follow-up and requiring intervention

  12 Months

• Percentage of Participants With Freedom From Treatment Failure at 12 Months Post-procedure Using the Boston Scientific Cardiac Cryoablation System With POLARx Cryoablation Balloon Catheter Models

  This measure reports the observed failure-free rate at 12 Months post index procedure. Failure defined as: * Failure to achieve acute procedural success in the index procedure * Any documented recurrent AF episode(s), or new onset of AFL or AT events: * ≥ 30 seconds in duration from any clinical recording devices considered standard of care at the study center (excluding insertable loop recorders)or * ≥10-second of continuous AF, AFL or AT documented on any 12-lead ECG between Days 91 and 12-Month follow-up * Any of the following interventions for atrial fibrillation, or new onset of atrial flutter or atrial tachycardia between days 91 and 12 Month Follow Up: * Repeat procedure * Electrical and/or pharmacological cardioversion for AF/AFL/AT * Prescribed a higher dose of any AAD documented at baseline or a new AAD not documented at baseline. * Hospitalization for AF/AT/AFL

  12 Months

Study Arms (1)

Cryoablation

EXPERIMENTAL

Subjects undergoing cardiac ablation procedure with the Boston Scientific Cardiac Cryoablation System.

Device: Boston Scientific Cardiac Cryoablation System

Interventions

Boston Scientific Cardiac Cryoablation System DEVICE

The Boston Scientific Cardiac Cryoablation System is intended for ablation and electrical mapping of the pulmonary veins for pulmonary vein isolation (PVI) in the ablation treatment of patients with paroxysmal atrial fibrillation (PAF).The main devices and components of the system consists of the following: * POLARx™ or POLARx™ FIT Cryoablation Catheter * POLARMAP™ Catheter * POLARSHEATH™ * SMARTFREEZE™ Console * Diaphragm Movement Sensor (DMS) * Related Accessories

Cryoablation

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subjects indicated for drug refractory, recurrent symptomatic PAF treatment with the Cryoablation System, per physician's medical judgement, and as per standard of care
• Subjects who are willing and capable of providing informed consent;
• Subjects who are willing and capable of participating in all testing associated with this clinical study at an approved clinical investigational center;

You may not qualify if:

• Any known contraindication to an AF ablation or anticoagulation, including those listed in the IFU as legally approved conditions;
• Any prior LA ablation;
• Known or pre-existing severe PV Stenosis;
• Subjects with severe valvular disease OR with a prosthetic - mechanical or biological - heart valve (not including valve repair and annular rings);
• Presence of any pulmonary vein stents;
• Subjects with active systemic infection;
• Subject is unable or not willing to complete follow-up visits and examination for the duration of the study;- Subjects with life expectancy ≤ 1 year per investigator's medical judgement;
• Women of childbearing potential who are, or plan to become, pregnant during the time of the study (assessment per investigator's discretion);

Sponsors & Collaborators

• Boston Scientific Corporation: lead

Study Sites (6)

Mercy Gilbert Medical Center

Gilbert, Arizona, 85297, United States

Location

Banner University Medical Center Phoenix

Phoenix, Arizona, 85006, United States

Location

Torrance Memorial Medical Center

Torrance, California, 90505, United States

Location

Bethesda North Hospital

Cincinnati, Ohio, 45242, United States

Location

University of Texas Medical Branch - Galveston

Galveston, Texas, 77555, United States

Location

Aurora Health

Grafton, Wisconsin, 53024, United States

Location

MeSH Terms

Conditions

Atrial Fibrillation

Condition Hierarchy (Ancestors)

Arrhythmias, Cardiac; Heart Diseases; Cardiovascular Diseases; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Wilber W Su, MD,FACC,FHRS

  Banner- University Medical Group- Heart Center, Phoenix, AZ, USA

  STUDY CHAIR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: prospective, single arm study

Study Record Dates

• First Submitted: December 6, 2023
• First Posted: December 14, 2023
• Study Start: June 28, 2024
• Primary Completion: May 1, 2026
• Study Completion (Estimated): May 1, 2029
• Last Updated: May 1, 2026

Record last verified: 2026-04

Data Sharing

• IPD Sharing: Will not share

Locations

US (6)